ADVANCES IN ONCOLOGY: THE ROLE OF IMMUNOTHERAPY IN TREATING SOLID TUMORS
Keywords:
Cancer immunotherapy, immune checkpoint inhibitors, solid tumors, PD-1/PD-L1, CAR-T cells, tumor microenvironment, precision oncology, cancer vaccine, biomarkers, clinical outcomesAbstract
In the past decade, immunotherapy has revolutionized the field of oncology, offering new hope in the battle against solid tumors. Unlike conventional chemotherapy or radiotherapy, immunotherapy utilizes the patient’s immune system to identify and destroy malignant cells. It represents a paradigm shift in cancer treatment, particularly in cases where traditional therapies have failed or proven insufficient. This article provides an in-depth overview of the development, mechanisms, and current applications of immunotherapy in the treatment of solid tumors, including statistical evaluations of efficacy in various cancer types. The article also explores challenges, limitations, and the future direction of immunotherapy in the global fight against cancer.
Downloads
References
G‘iyosov A.T., To‘xtasinova M.B. (2023). Zamonaviy onkologiyada immunoterapiya yondashuvlari. Toshkent: O‘zMU nashriyoti.
Raxmatova Z.B. (2022). Qattiq o‘simtalarni davolashda immunologik terapiyaning o‘rni. Samarqand: SamDTU ilmiy jurnali.
International Sources
World Health Organization (2023). Cancer Fact Sheet. Geneva: WHO.
Ribas A., Wolchok J.D. (2018). Cancer immunotherapy using checkpoint blockade. Science, 359(6382), 1350–1355.
Hellmann M.D., et al. (2020). Nivolumab plus ipilimumab in advanced NSCLC. New England Journal of Medicine, 382(22), 2093–2104.
Hodi F.S., et al. (2018). Survival trends in advanced melanoma with checkpoint inhibitors. Journal of Clinical Oncology, 36(15), 1675–1684.
Sharma P., Allison J.P. (2020). The future of immune checkpoint therapy. Science, 348(6230), 56–61.
Hanna N.H., et al. (2021). Immunotherapy in solid tumors: From development to clinical implementation. The Lancet Oncology, 22(10), e450–e465.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.
